Belite Bio (BLTE) said late Wednesday it signed a securities purchase deal with a new healthcare investor to buy and sell 258,309 of its American depositary shares and warrants to buy equal amount of American depositary shares at $58.07 per ADS in a registered direct offering for gross proceeds of roughly $15 million.
The biopharmaceutical company intends to close the offering around Friday, and plans to use the net proceeds for working capital and general corporate purposes, it added.
Belite Bio's stock was down more than 1% in recent Thursday premarket activity.
Price: 57.11, Change: -0.96, Percent Change: -1.65
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.